Budukh Atul Madhukar, Thakur Jarnail S, Dora Tapas Kumar, Kadam Prithviraj R, Bagal Sonali S, Patel Kamalesh Kumar, Goel Alok K, Sancheti Sankalp M, Gulia Ashish R, Chaturvedi Pankaj P, Dikshit Rajesh P, Badwe Rajendra A
Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Department of Community Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Urol. 2023 Apr-Jun;39(2):148-155. doi: 10.4103/iju.iju_38_23. Epub 2023 Mar 31.
There is a scarcity of population-based prostate cancer survival data in India. We assessed the population-based, overall survival of patients with prostate cancer from the Sangrur and Mansa cancer registries of the Punjab state, India.
In the year 2013-2016, a total of 171 prostate cancer cases were registered in these two registries. Based on these registries, survival analysis was performed using the date of diagnosis as the starting date and the last follow-up date being December 31, 2021 or the date of death. Survival was calculated using STATA software. Relative survival was calculated using the Pohar Perme method.
Follow up was available for all the registered cases. Of the 171 cases, 41 (24%) were alive and 130 (76.0%) were dead. Of the prescribed treatments, 106 (62.7%) cases completed the treatment and 63 (37.3%) cases did not complete the treatment. Overall, 5-year age-standardized prostate cancer relative survival was 30.3%. Patients who completed the treatment had a 7.8 times higher 5-year relative survival (45.5%) compared to those who did not (5.8%). The difference between the two groups is statistically significant (hazard ratio 0.16, 95% confidence interval [0.10-0.27]).
To improve survival, we need to raise awareness in the community and among primary physicians so that prostate cancer cases can reach the hospital early and should be treated effectively. The cancer center should develop the systems in their hospital so that there will be no hurdles to the patients in treatment completion. We found a low overall relative survival among patients of prostate cancer in these two registries. Patients who received treatment had a significantly higher survival.
印度缺乏基于人群的前列腺癌生存数据。我们评估了印度旁遮普邦桑格鲁尔和曼萨癌症登记处前列腺癌患者的基于人群的总体生存率。
在2013年至2016年期间，这两个登记处共登记了171例前列腺癌病例。基于这些登记处的数据，以诊断日期为起始日期，最后随访日期为2021年12月31日或死亡日期进行生存分析。使用STATA软件计算生存率。采用波哈尔·佩尔梅方法计算相对生存率。
所有登记病例均有随访信息。171例病例中，41例（24%）存活，130例（76.0%）死亡。在规定的治疗中，106例（62.7%）完成了治疗，63例（37.3%）未完成治疗。总体而言，5年年龄标准化前列腺癌相对生存率为30.3%。完成治疗的患者5年相对生存率（45.5%）比未完成治疗的患者（5.8%）高7.8倍。两组之间的差异具有统计学意义（风险比0.16，95%置信区间[0.10 - 0.27]）。
为提高生存率，我们需要提高社区和基层医生的意识，以便前列腺癌病例能够尽早到医院就诊并得到有效治疗。癌症中心应在其医院建立相关系统，使患者在完成治疗过程中不会遇到障碍。我们发现这两个登记处的前列腺癌患者总体相对生存率较低。接受治疗的患者生存率明显更高。
